Announcement PDF RNS Number : 0510I OptiBiotix Health PLC 25 March 2024 OptiBiotix Health plc ("OptiBiotix" or the "Company") Placing, Subscription and Director Dealing OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces it has raised in aggregate £1,350,500 through the issue of 6,752,500 new ordinary shares of 2 pence each in the Company ("Fundraise Shares") at a price of 20 pence per share ("Issue Price") (together, the "Fundraise") handled by Peterhouse Capital Limited. The Fundraise comprises a placing of 6,627,500 new ordinary shares at the Issue Price, raising gross proceeds of £1,325,500 (the "Placing") and a subscription for 125,000 new ordinary shares at the Issue Price, raising gross proceeds of £25,000, by Graham Myers, a director of the Company (the "Subscription"). Following the Subscription, Graham Myers will be interested in 125,000 ordinary shares in the Company, representing 0.13 per cent. of the Company's issued share capital following Admission (as defined below). The net proceeds of the Fundraise will be utilised to invest in driving sales growth by:1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales; 2. increased presence of the Company's stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners; 3. investing in marketing the Company's products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and 4. launch its second generation SweetBiotix and MicroBiome Modulator products. Related Party Transaction The participation of Graham Myers in the Subscription is a related party transaction pursuant to AIM Rule 13 (the "Transaction"). The directors independent of the Transaction, having consulted with the Company's nominated adviser, believe that the terms of the Transaction are fair and reasonable insofar as shareholders are concerned. Admission Application will be made to the London Stock Exchange to admit the 6,752,500 new Fundraise Shares to trading on AIM ("Admission"). Admission of the new Ordinary Shares is expected to occur on or around 28 March 2024. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Total Voting Rights For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 97,943,161 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules. Stephen O'Hara, CEO of OptiBiotix, commented: "The Company has made strong progress over the last 12 months with our first-generation products returning to sales growth, a number of wellknown corporate partners reaching agreements (e.g. Tata, Brenntag, Morepen) and the launch of new products with major brands (MuscleTech, Dr Morepen) in new channels. We are also seeing growth of online sales, particularly in China, and the potential to replicate this success in other territories, such as India and the USA. "More recently we have seen strong interest in SlimBiome from partners in the USA looking for a natural, clinically proven alternative to the anti-obesity drugs currently available. Given the scale of the opportunities, the Board has decided to raise additional capital to capitalise on these growth opportunities and build shareholder value." This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. For further information, please contact: OptiBiotix Health plc Neil Davidson, Chairman Stephen O'Hara, Chief Executive www.optibiotix.com Contact via Walbrook below Cairn Financial Advisers LLP (NOMAD) Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880 Peterhouse Capital Limited (Joint Broker) Duncan Vasey/ Lucy Williams Tel: 020 7220 9797 Walbrook PR Ltd Anna Dunphy Mob: 07876 741 001 About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. Caution regarding forward looking statements Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated a. Name 2 Reason for notification a. Position/Status b. Initial notification/ Initial Notification Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 3 Graham Myers Finance Director a. Name OptiBiotix Health Plc b. LEI 213800UKYQFT941QHS14 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Ordinary shares of 2p each financial instrument, type of instrument ISIN: GB00BP0RTP38 Identification Code Nature of the Subscription of 125,000 ordinary shares in the Company transaction a. b. c. Price(s) and volume(s) Price(s) per share Volume(s) 20p 125,000 d. - Aggregated information Volume - Price e. f. Date of the transaction Place of the transaction 22 March 2024 London Stock Exchange, AIM This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END IOEJTMLTMTTTBAI